Intech Investment Management LLC Has $6.67 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Intech Investment Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 147.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,410 shares of the biopharmaceutical company’s stock after acquiring an additional 83,105 shares during the quarter. Intech Investment Management LLC’s holdings in Halozyme Therapeutics were worth $6,665,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at $217,000. CIBC Asset Management Inc bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth about $211,000. Natixis Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 86.7% during the 3rd quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company’s stock worth $6,958,000 after buying an additional 56,461 shares during the period. TrinityPoint Wealth LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at about $214,000. Finally, Quest Partners LLC raised its holdings in Halozyme Therapeutics by 1,386.0% in the 3rd quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 9,134 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Trading Down 0.7 %

HALO opened at $62.54 on Wednesday. The stock has a market capitalization of $7.70 billion, a price-to-earnings ratio of 18.23, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53. The company has a 50-day simple moving average of $57.53 and a 200 day simple moving average of $54.61.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.